Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Publication on the Use of Excellagen® for Vascular Repair

    NEXT STORY
    Study Reveals Individuals with Behavioral Health Conditions in Addition to Physical Conditions Drive High Total Healthcare Costs; Small Portion Spent on Behavioral Treatment, Vast Majority Spent on Physical Treatment
    PREV STORY
    Zealand Pharma announces acceleration of U.S. commercial operations through the completion of the Valeritas acquisition; FDA acceptance of New Drug Application submission for the dasiglucagon HypoPal® rescue pen; pipeline progress including
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences

    author_avatar
    NASDAQ Market News

    FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Capital Notes into shares

    FIT Biotech Oy Company release August 28, 2017 at 10:00 AM EET Conversion of ...

    author_avatar
    NASDAQ Market News

    Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results

    author_avatar
    NASDAQ Market News